Decreased Tissue Kallikrein Levels and the Risk of Ischemic Stroke: A Community-Based Cross-Sectional Study in China

References

• Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. doi:10.1161/CIR.0000000000000757
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–e743. doi:10.1161/CIR.0000000000000950
   PubMed Web of Science ®Google Scholar
• Chao BH, Yan F, Hua Y, et al. Stroke prevention and control system in China: CSPPC-Stroke program. Int J Stroke. 2021;16(3):265–272. doi:10.1177/1747493020913557
   PubMed Web of Science ®Google Scholar
• Feigin VL, Nguyen G; Collaborators GBDLRoS. Global, regional, and country-specific lifetime risks of Stroke, 1990 and 2016. N Engl J Med. 2018;379:2429–2437.
   PubMed Web of Science ®Google Scholar
• Hecquet C, Tan F, Marcic BM, Erdos EG. Human Bradykinin B2 receptor is activated by kallikrein and other serine proteases. Mol Pharmacol. 2000;58(4):828–836. doi:10.1124/mol.58.4.828
   PubMed Web of Science ®Google Scholar
• Chao J, Bledsoe G, Yin H, Chao L. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem. 2006;387:665–675.
   PubMed Web of Science ®Google Scholar
• Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol. 2005;90(3):291–298. doi:10.1113/expphysiol.2004.028464
   PubMed Web of Science ®Google Scholar
• Potier L, Waeckel L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F. Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency. Biol Chem. 2013;394(3):329–333. doi:10.1515/hsz-2012-0332
   PubMed Web of Science ®Google Scholar
• Feng J, Dong C, Long Y, et al. Elevated Kallikrein-binding protein in diabetes impairs wound healing through inducing macrophage M1 polarization. Cell Commun Signal. 2019;17(1):60. doi:10.1186/s12964-019-0376-9
   PubMed Web of Science ®Google Scholar
• Chao J, Chao L. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Pharmacol Res. 1997;35(6):517–522. doi:10.1006/phrs.1997.0179
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ding H, Yan J, et al. Plasma tissue kallikrein level is negatively associated with incident and recurrent stroke: a multicenter case-control study in China. Ann Neurol. 2011;70(2):265–273. doi:10.1002/ana.22404
   PubMed Web of Science ®Google Scholar
• Yang J, Su J, Wan F, et al. Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-kappaB and activating Nrf2 signaling pathway in rats. Exp Ther Med. 2017;14(2):1163–1170. doi:10.3892/etm.2017.4614
   PubMed Web of Science ®Google Scholar
• Shi R, Yuan K, Hu B, et al. Tissue kallikrein alleviates cerebral ischemia-reperfusion injury by activating the B2R-ERK1/2-CREB-Bcl-2 signaling pathway in diabetic rats. Oxid Med Cell Longev. 2016;2016:1843201. doi:10.1155/2016/1843201
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ran X, Wang DW. Relation of plasma tissue kallikrein levels to presence and severity of coronary artery disease in a Chinese population. PLoS One. 2014;9(3):e91780. doi:10.1371/journal.pone.0091780
   PubMed Web of Science ®Google Scholar
• Li H, Pei F, Shao L, et al. Prevalence and risk factors of abnormal left ventricular geometrical patterns in untreated hypertensive patients. BMC Cardiovasc Disord. 2014;14(1):136. doi:10.1186/1471-2261-14-136
   PubMed Web of Science ®Google Scholar
• Slee VN. The international classification of diseases: ninth revision (ICD-9). Ann Intern Med. 1978;88(3):424–426. doi:10.7326/0003-4819-88-3-424
   PubMed Web of Science ®Google Scholar
• Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271–2306. doi:10.1161/CIRCULATIONAHA.109.192663
   PubMed Web of Science ®Google Scholar
• 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17(2):151–183.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Brash AR. Arachidonic acid as a bioactive molecule. J Clin Invest. 2001;107(11):1339–1345. doi:10.1172/JCI13210
   PubMed Web of Science ®Google Scholar
• Ader JL, Tran-van T, Praddaude F. Renal tissue kallikrein in newborn and young SHR. Am J Hypertens. 1988;1(3 Pt 3):53S–55S. doi:10.1093/ajh/1.3.53S
   PubMed Web of Science ®Google Scholar
• Wang J, Xiong W, Yang Z, et al. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension. 1994;23(2):236–243. doi:10.1161/01.HYP.23.2.236
   PubMed Web of Science ®Google Scholar
• Yuan G, Deng J, Wang T, et al. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5ʹ-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007;148(5):2016–2026. doi:10.1210/en.2006-0602
   PubMed Web of Science ®Google Scholar
• Chao J, Yin H, Gao L, et al. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008;52(4):715–720. doi:10.1161/HYPERTENSIONAHA.108.114587
   PubMed Web of Science ®Google Scholar
• Robles NR, Cerezo I, Hernandez-Gallego R. Renin-angiotensin system blocking drugs. J Cardiovasc Pharmacol Ther. 2014;19(1):14–33. doi:10.1177/1074248413501018
   PubMed Web of Science ®Google Scholar
• Regoli D, Gobeil F. Kinins and peptide receptors. Biol Chem. 2016;397(4):297–304. doi:10.1515/hsz-2015-0240
   PubMed Web of Science ®Google Scholar
• Bader M. Molecular interactions of vasoactive systems in cardiovascular damage. J Cardiovasc Pharmacol. 2001;38(Suppl 2):S7–9. doi:10.1097/00005344-200111002-00003
   PubMed Web of Science ®Google Scholar
• Wang T, Hou LB, Liu ZJ, et al. Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats. Acta Pharmacol Sin. 2007;28(12):1898–1906. doi:10.1111/j.1745-7254.2007.00677.x
   PubMed Web of Science ®Google Scholar
• Ribeiro MS, Dellalibera-Joviliano R, Becari C, et al. Characterization of the kallikrein-kinin system, metalloproteinases, and their tissue inhibitors in the in-stent restenosis after peripheral percutaneous angioplasty. Ann Vasc Surg. 2014;28(4):1005–1015. doi:10.1016/j.avsg.2013.11.014
   PubMed Web of Science ®Google Scholar
• Tang M, He F, Ma L, Liu P, Wang J, Zhu X. Bradykinin receptors in ischemic injury. Curr Neurovasc Res. 2018;15(4):359–366. doi:10.2174/1567202616666181123151629
   PubMed Web of Science ®Google Scholar
• Murakami H, Yayama K, Miao RQ, Wang C, Chao L, Chao J. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension. 1999;34(2):164–170. doi:10.1161/01.HYP.34.2.164
   PubMed Web of Science ®Google Scholar
• Chao J, Shen B, Gao L, Xia CF, Bledsoe G, Chao L. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem. 2010;391(4):345–355. doi:10.1515/bc.2010.042
   PubMed Web of Science ®Google Scholar
• Liu Y, Hashizume K, Chen Z, et al. Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors. Neurol Res. 2001;23(4):379–387. doi:10.1179/016164101101198596
   PubMed Web of Science ®Google Scholar
• van Diepen JA, Berbee JF, Havekes LM, Rensen PC. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis. 2013;228(2):306–315. doi:10.1016/j.atherosclerosis.2013.02.028
   PubMed Web of Science ®Google Scholar
• Charla E, Mercer J, Maffia P, Nicklin SA. Extracellular vesicle signalling in atherosclerosis. Cell Signal. 2020;75:109751. doi:10.1016/j.cellsig.2020.109751
   PubMed Web of Science ®Google Scholar
• Montanari D, Yin H, Dobrzynski E, et al. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes. 2005;54(5):1573–1580. doi:10.2337/diabetes.54.5.1573
   PubMed Web of Science ®Google Scholar
• Wei Z, Lyu Y, Yang X, Chen X, Zhong P, Wu D. Therapeutic values of human urinary kallidinogenase on cerebrovascular diseases. Front Neurol. 2018;9:403. doi:10.3389/fneur.2018.00403
   PubMed Web of Science ®Google Scholar
• Ma N, Zhao ZA, Zhang NN, Chen HS. Intra-arterial human urinary kallidinogenase alleviates brain injury in rats with permanent middle cerebral artery occlusion through PI3K/AKT/FoxO1 signaling pathway. Brain Res. 2018;1687:129–136. doi:10.1016/j.brainres.2018.02.049
   PubMed Web of Science ®Google Scholar
• Miao J, Deng F, Zhang Y, Xie HY, Feng JC. Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke. Neurosciences. 2016;21:126–130.
   PubMed Web of Science ®Google Scholar